Skip to content
Infectious Disease



Resources for Health Care Providers

*Suspected or confirmed active tuberculosis disease is a reportable condition in Alaska.*  
Cases should be reported to the Alaska TB Program within 2 business days.  Please call the Section of Epidemiology at 907-269-8000, or complete the appropriate report form and fax to 907-561-4239.
 
*NOTICE of PRI​FTIN® (RIFAPENTINE) impurity issue 7-1-20*
In June 2020 Sanofi alerted the Division of Tuberculosis Elimination, other health agencies, and stakeholders worldwide about a newly detected impurity in Priftin®. The impurity, 1-cyclopentyl-4-nitrosopiperazine, is a nitrosamine and a potential carcinogen.  Read more at the links below.


Letter to Alaska providers/public health nurses​​​

Information from CDC​


Provider Toolkit


Screening/Assessment

The USPSTF recommends screening for latent TB infection (LTBI) in populations at increased risk.  Finding and treating patients with LTBI is key to controlling the TB epidemic.

Testing/Diagnosis
IGRA (blood) testing is​ now approved for all persons>2 years of age and has some advantages over TST (skin test), especially in foreign-born persons who may have received BCG vaccination in the past.
Treatment for LTBI
There are now shorter-course regimens which make LTBI treatment easier.  It is very important to rule out active TB disease prior to starting treatment for LTBI.
Treatment for Active TB
Patient Education
Training/Resources

 
For Civil Surgeons


TB Reports/Bulletins

Webinars

 

 

 




​​​​​​